SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458507082941v1
1352458507082941v2
14/2/272    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sadiq, S. A.
Right arrow Articles by Sara, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadiq, S. A.
Right arrow Articles by Sara, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS

Saud A. Sadiq*, Mustapha Rammal, and Gabriel Sara

Division of Hematology/Oncology, Department of Medicine, St. Luke's – Roosevelt Hospital, New York, N.Y.

* To whom correspondence should be addressed.


  Abstract

We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone treatment in MS. This underscores the need for only using mitoxantrone in severe treatmentunresponsive cases of MS.

Key Words: chronic myeloid leukemia; multiple sclerosis; mitoxantrone

First published on November 6, 2007, doi:10.1177/1352458507082941

Multiple Sclerosis 2008;14:272.

A more recent version of this article appeared on March 1, 2008
 This version was published on January 31, 2008
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
A. M Pascual, N. Tellez, I. Bosca, J. Mallada, A. Belenguer, I. Abellan, A. P Sempere, P. Fernandez, M. J. Magraner, F. Coret, et al.
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required
Multiple Sclerosis, November 1, 2009; 15(11): 1303 - 1310.
[Abstract] [PDF]


Advertisement